RANI Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-0.067

-75.31%

-0.140

-36.36%

-0.160

-11.11%

Estimates Revision

The market is revising Upward the revenue expectations for Rani Therapeutics Holdings, Inc. (RANI) for FY2025, with the revenue forecasts being adjusted by 2759.98% over the past three months. During the same period, the stock price has changed by 205.54%.

Revenue Estimates for FY2025

Revise Upward

+2759.98%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-19.14%

In Past 3 Month

Stock Price

Go Up

+205.54%

In Past 3 Month

3 Analyst Rating

Wall Street analysts forecast RANI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RANI is 10.00 USD with a low forecast of 9.00 USD and a high forecast of 11.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

9.00

Averages

10.00

High

11.00

Current: 0.000

Low

9.00

Averages

10.00

High

11.00

H.C. Wainwright

Brandon Folkes

Buy

initiated

$11

2025-10-21

Reason

H.C. Wainwright

Brandon Folkes

Price Target

$11

2025-10-21

initiated

Buy

Reason

H.C. Wainwright analyst Brandon Folkes assumed coverage of Rani Therapeutics with a Buy rating and $11 price target. The firm believes the company has "three significant value drivers," its platform technology RaniPill, a recently announced collaboration agreement with Chugai Pharmaceutical for the development of a hemophilia product, and potentially an additional five drug targets, as well as RT-114, an oral GLP-1/GLP-2 dual agonist candidate. It expects data readouts on RT-114 to be the biggest driver of near-term value creation for Rani shares.

Maxim Group

Maxim

Buy

maintain

$5 -> $10

2025-10-20

Reason

Maxim Group

Maxim

Price Target

$5 -> $10

2025-10-20

maintain

Buy

Reason

Maxim raised the firm's price target on Rani Therapeutics to $10 from $5 and keeps a Buy rating on the shares after the company announced a licensing deal with Chugai Pharmaceutical for RaniPill technology and a concurrent private placement to raise $60M in proceeds. The Chugai deal offers both non-dilutive financing as well as "key validation" for RaniPill, the analyst tells investors.

Oppenheimer

Outperform

NULL

downgrade

$14 -> $4

2025-05-16

Reason

Oppenheimer

Price Target

$14 -> $4

2025-05-16

downgrade

Outperform

NULL

Reason

Oppenheimer lowered the firm's price target on Rani Therapeutics to $4 from $14 and keeps an Outperform rating on the shares following quarterly and business update. The firm anticipates a mid-2025 initiation of the Phase 1 study for RT-114, an oral RaniPill containing 200microL of ProGen's GLP-1/GLP-2 receptor agonist, PG-102. In March, Rani presented preclinical data demonstrating comparable bioavailability between RT-114 and subcutaneous PG-102 supporting its potential as an effective oral obesity treatment. Oppenheimer views Rani's expansion into obesity as a value-driver, differentiated by tolerability and flexible dosing. Given the company's financial position and advancing RT-114/obesity becoming its prime focus, the firm removes RT-111/psoriasis from its valuation.

HC Wainwright & Co.

Mitchell Kapoor

Strong Buy

Reiterates

2025-04-03

Reason

HC Wainwright & Co.

Mitchell Kapoor

Price Target

2025-04-03

Reiterates

Strong Buy

Reason

Canaccord Genuity

Edward Nash

Strong Buy

Maintains

2025-02-26

Reason

Canaccord Genuity

Edward Nash

Price Target

2025-02-26

Maintains

Strong Buy

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Strong Buy

Reiterates

2025-02-07

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Price Target

2025-02-07

Reiterates

Strong Buy

Reason

Valuation Metrics

The current forward P/E ratio for Rani Therapeutics Holdings Inc (RANI.O) is -2.58, compared to its 5-year average forward P/E of -5.46. For a more detailed relative valuation and DCF analysis to assess Rani Therapeutics Holdings Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-5.46

Current PE

-2.58

Overvalued PE

-0.04

Undervalued PE

-10.88

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-2.08

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.09

Undervalued EV/EBITDA

-4.24

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

397.58

Current PS

11.29

Overvalued PS

1194.03

Undervalued PS

-398.88

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders areBuying! The selling amount has increased 2422.5% over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders areBuying! The selling amount has increased 2422.5% over the last month.

Sold

Bought

RANI News & Events

Events Timeline

No data

News

9.5

2025-11-04NASDAQ.COM

Biotech Stocks Soar in After-Hours Trading: TCMD, BDSX, and EXAS Take the Lead

5.0

2025-10-28NASDAQ.COM

Insider Buying Update for Tuesday, October 28: RANI and KO

9.0

2025-10-23NASDAQ.COM

VTYX, MEDP, INBX Surge in After-Hours Trading Following Important Announcements

People Also Watch

Frequently Asked Questions

What is Rani Therapeutics Holdings Inc (RANI) stock price today?

The current price of RANI is 1.4 USD — it has increased 0.72 % in the last trading day.

What is Rani Therapeutics Holdings Inc (RANI)'s business?

Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. The Company has developed the RaniPill capsule, which is a proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. The RaniPill capsule is designed to deliver a variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. It has two configurations of the platform: the RaniPill GO and the RaniPill HC. The RaniPill GO is designed to deliver up to a 3 mg dose of drug in microtablet form with high bioavailability. It is also developing a high-capacity version of the RaniPill capsule known as the RaniPill HC. Its product candidate pipeline includes obesity programs (RT-114 and RT-116), immunology programs (RT-105 and RT-111) and endocrinology programs (RT-102 and RT-110).

What is the price predicton of RANI Stock?

What is Rani Therapeutics Holdings Inc (RANI)'s revenue for the last quarter?

Rani Therapeutics Holdings Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

What is Rani Therapeutics Holdings Inc (RANI)'s earnings per share (EPS) for the last quarter?

Rani Therapeutics Holdings Inc. EPS for the last quarter amounts to -0.12 USD, decreased -50.00 % YoY.

What changes have occurred in the market's expectations for Rani Therapeutics Holdings Inc (RANI)'s fundamentals?

How many employees does Rani Therapeutics Holdings Inc (RANI). have?

Rani Therapeutics Holdings Inc (RANI) has 105 emplpoyees as of January 10 2026.

What is Rani Therapeutics Holdings Inc (RANI) market cap?

Today RANI has the market capitalization of 170.12M USD.